Akums Drugs & Pharmaceuticals FY26 Earnings Update

Akums Drugs & Pharmaceuticals concluded fiscal year 2026 with strong momentum, reporting robust performance in its Contract Development and Manufacturing Organization (CDMO) segment. This segment achieved double-digit volume growth, indicating a positive trajectory despite earlier market challenges.

Key Financials and Segment Performance

The company announced its financial results for the fourth quarter and full year ended March 31, 2026. The CDMO business was a standout performer, showing significant volume expansion. Akumentis, the domestic branded formulation business, recorded modest revenue growth and margin improvement. The Active Pharmaceutical Ingredient (API) business, however, continued to struggle with pricing pressures, particularly in cephalosporin, resulting in ongoing losses. Akums plans to gradually shift its API focus to higher-margin products and regulated markets to address this.
The trade generics business has been stabilized and now operates with a smaller, profit-focused model.

Strategic Resilience and Shareholder Returns

Despite facing headwinds in the first half of FY26 from API price erosion and slow volume growth, Akums demonstrated resilience. The company's emphasis on strong client relationships and high manufacturing quality has been key to its performance. Significant progress in international markets, including the EU and Zambia, highlights the CDMO segment as a promising growth area. Akums recommended a total dividend of INR 3 per equity share for FY26, comprising a final dividend of INR 1 and a special dividend of INR 2, providing a direct return to shareholders. Nevertheless, the persistent losses in the API segment remain a point of concern, although management is working towards a turnaround.

Operational Investments and Digital Transformation

Akums Drugs & Pharmaceuticals has been actively navigating a dynamic market environment. To counter earlier challenges from declining API prices and subdued volumes, the company intensified its focus on strengthening client relationships and enhancing manufacturing quality. Substantial investments have been made in capacity expansion, research and development, and modernization. These include new facilities and the implementation of digital transformation initiatives such as SAP S/4HANA and Darwinbox.

Future Projections and API Turnaround Plan

Looking ahead, Akums projects continued double-digit volume growth in its CDMO segment through the first two quarters of FY27. The company anticipates API prices will stabilize in the first half of FY27. The domestic branded formulation business is expected to grow in line with the Indian Pharmaceutical Market (IPM), targeting double-digit top-line growth. For the API segment, Akums aims to significantly reduce losses and achieve EBITDA positivity in the medium term. This plan is supported by European inspections and a strategic shift towards regulated markets.

Potential Risks

Global environmental uncertainties pose a risk, potentially leading to price volatility, especially impacting the API business. The continued pricing pressure on cephalosporin has resulted in ongoing losses for this segment. Disruptions in specific markets for domestic branded formulations and limited expected contributions from the trade generics business also present challenges.

Industry Strategy

While specific peer data was not detailed, Akums' strategy aligns with industry trends focusing on CDMO growth, international expansion (demonstrated by EU GMP accreditation and a Zambia partnership), and operational efficiency. These are common approaches for pharmaceutical companies aiming to diversify revenue and improve margins. The company's success in scaling operations in regulated markets will be crucial for competing with established global players.

Key Performance Metrics

• Capital expenditure for FY26 reached INR 222 crores.
• The capital expenditure target for the current year (FY27) is INR 300 crores.
• A final dividend of INR 1 per equity share and a special dividend of INR 2 per equity share were recommended for FY26.
• A European contract is expected to contribute EUR 35 million annually for six years.
• A contract in Zambia is valued at $25 million per year for FY27 and FY28.
• Akums holds a 51% stake in a Zambian facility with a $45 million investment.

Investor Watchlist

Investors will closely watch the successful ramp-up of new facilities, particularly the injectable facility, and progress in obtaining international regulatory approvals. The company's ability to reduce API segment losses and achieve profitability, alongside sustained double-digit CDMO growth, will be critical indicators in the upcoming quarters.